Lupin Ltd (LUPIN) – Company Profile and SWOT Analysis

Lupin Ltd (LUPIN) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Lupin Ltd (Lupin) is a global pharmaceutical company primarily engaged in the development and distribution of a diverse range of healthcare products. The company's portfolio includes products, with a focus on generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. Lupin's products cater to various therapeutic areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health, serving patients and communities worldwide. The company undertakes extensive research and development activities of pharmaceuticals for the treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, diabetes, tuberculosis, inflammation and others. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company's products are distributed worldwide, indicating a broad distribution network. Lupin operates across multiple geographic locations, including the US, LATAM, APAC, EMEA, and India, targeting key markets in these regions. Lupin is headquartered in Mumbai, Maharashtra, India.

Scope

• Detailed information on Lupin Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Lupin Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Lupin Ltd including a breakdown and examination of key business segments

• News about Lupin Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Lupin Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Lupin Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Lupin Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Cipla Ltd

Abbott India Ltd

Aarti Drugs Ltd

Sun Pharmaceutical Industries Ltd

Dr. Reddy's Laboratories Ltd

Intas Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd

Divi's Laboratories Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Lupin Ltd - Key Facts

Lupin Ltd - Key Employees

Lupin Ltd - Key Employee Biographies

Lupin Ltd - Major Products and Services

Lupin Ltd - History

Lupin Ltd - Company Statement

Lupin Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Lupin Ltd - Business Description

Business Segment: Others

Overview

Performance

Business Segment: Pharmaceuticals

Overview

Performance

Geographical Segment: India

Performance

Geographical Segment: Others

Performance

Geographical Segment: USA

Performance

R&D Overview

Lupin Ltd - Corporate Strategy

Lupin Ltd - SWOT Analysis

SWOT Analysis - Overview

Lupin Ltd - Strengths

Lupin Ltd - Weaknesses

Lupin Ltd - Opportunities

Lupin Ltd - Threats

Lupin Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Lupin Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

Jul 16, 2024: Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets

Jul 12, 2024: Lupin Receives EIR from U.S. FDA for its Dabhasa Facility

Jun 22, 2024: Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

Jun 14, 2024: Lupin Announces Closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations

May 15, 2024: Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office

May 06, 2024: Lupin Q4 FY2024 Results

May 06, 2024: Lupin : Announces Board changes

Apr 23, 2024: Lupin Receives EIR from US FDA for its Aurangabad Manufacturing Facility

Apr 23, 2024: Partex Partners with Lupin to Revolutionize Drug Discovery with AI-Driven Asset Search & Evaluation

Apr 03, 2024: Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Lupin Ltd, Key Facts

Lupin Ltd, Key Employees

Lupin Ltd, Key Employee Biographies

Lupin Ltd, Major Products and Services

Lupin Ltd, History

Lupin Ltd, Other Locations

Lupin Ltd, Subsidiaries

Lupin Ltd, Joint Venture

Lupin Ltd, Key Competitors

Lupin Ltd, Ratios based on current share price

Lupin Ltd, Annual Ratios

Lupin Ltd, Annual Ratios (Cont…1)

Lupin Ltd, Annual Ratios (Cont…2)

Lupin Ltd, Interim Ratios

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Lupin Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Lupin Ltd, Performance Chart (2020 – 2024)

Lupin Ltd, Ratio Charts

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports